Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system

26 Jan 2023

Abstract excerpt

Several vaccine platforms have been developed to fight pathogenic threats, with Virus-Like Particles (VLPs) representing a very promising alternative to traditional platforms. VLPs trigger strong and lasting humoral and cellular immune responses with fewer safety concerns and higher stability than other platforms. The use of extensively characterized carrier VLPs modified with heterologous antigens was proposed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Transgenic Plants and Applications
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36776898
DOI: 10.3389/fimmu.2023.1088852

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis systemPMID 36776898Read ↗

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read ↗

Virus-like particles: flexible platforms for vaccine developmentSemantic proximity Read ↗

Virus‐like particles as powerful vaccination strategy against human virusesSemantic proximity Read ↗

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical developmentSemantic proximity Read ↗

Advances and challenges in enveloped virus-like particle (VLP)-based vaccinesSemantic proximity Read ↗

Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell PoolSemantic proximity Read ↗

Production of virus-like particles for vaccinesSemantic proximity Read ↗

Characterization of HIV‐1 virus‐like particles and determination of Gag stoichiometry for different production platformsSemantic proximity Read ↗

Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturingSemantic proximity Read ↗

Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particlesSemantic proximity Read ↗

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriersSemantic proximity Read ↗

A scalable cell-free manufacturing platform for two-step bioproduction of immunogenic conjugate vaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.